Literature DB >> 32244797

A Coil-to-Helix Transition Serves as a Binding Motif for hSNF5 and BAF155 Interaction.

Jeongmin Han1, Iktae Kim2, Jae-Hyun Park1, Ji-Hye Yun1, Keehyoung Joo3, Taehee Kim1, Gye-Young Park1, Kyoung-Seok Ryu4, Yoon-Joo Ko5, Kenji Mizutani6, Sam-Young Park6, Rho Hyun Seong7, Jooyoung Lee8, Jeong-Yong Suh2, Weontae Lee1.   

Abstract

Human SNF5 and BAF155 constitute the core subunit of multi-protein SWI/SNF chromatin-remodeling complexes that are required for ATP-dependent nucleosome mobility and transcriptional control. Human SNF5 (hSNF5) utilizes its repeat 1 (RPT1) domain to associate with the SWIRM domain of BAF155. Here, we employed X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and various biophysical methods in order to investigate the detailed binding mechanism between hSNF5 and BAF155. Multi-angle light scattering data clearly indicate that hSNF5171-258 and BAF155SWIRM are both monomeric in solution and they form a heterodimer. NMR data and crystal structure of the hSNF5171-258/BAF155SWIRM complex further reveal a unique binding interface, which involves a coil-to-helix transition upon protein binding. The newly formed αN helix of hSNF5171-258 interacts with the β2-α1 loop of hSNF5 via hydrogen bonds and it also displays a hydrophobic interaction with BAF155SWIRM. Therefore, the N-terminal region of hSNF5171-258 plays an important role in tumorigenesis and our data will provide a structural clue for the pathogenesis of Rhabdoid tumors and malignant melanomas that originate from mutations in the N-terminal loop region of hSNF5.

Entities:  

Keywords:  BAF155; NMR spectroscopy; X-ray crystallography; coupled folding and binding; hSNF5

Year:  2020        PMID: 32244797     DOI: 10.3390/ijms21072452

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  2 in total

1.  Special Issue "Selected Papers from the 8th Asia-Pacific NMR (APNMR) Symposium: Recent Advances in NMR Spectroscopy".

Authors:  Surajit Bhattacharjya; Daiwen Yang; Ho Sup Yoon
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

Review 2.  Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments.

Authors:  Carine Ngo; Sophie Postel-Vinay
Journal:  Biomedicines       Date:  2022-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.